ASCO 2022: ASCO & WHO to collaborate on quality indicators for cancer facilities worldwide
In a collaboration announced today, the American Society of Clinical Oncology, Inc.(ASCO) will work with…
Browsing: ASCO
ASCO 2022: Immunotherapy before surgery associated with improved survival for soft-tissue sarcoma
In a Phase II clinical trial, immune checkpoint blockade before surgery was associated with favourable…
ASCO 2022: Novel agent increases PFS for patients with the most common type of advanced breast cancer
The use of sacituzumab govitecan (Trodelvy) an antibody-drug conjugate, resulted in longer progression-free survival compared to…
ASCO 2022: Ibrutinib improves progression-free survival by 50% for older patients with newly diagnosed mantle cell lymphoma
Ibrutinib (Imbruvica) combined with bendamustine-rituximab improved progression-free survival by 50% for older patients with newly…
ASCO 2022: Nimotuzumab significantly improves overall survival for K-Ras wild-type advanced pancreatic cancer
The addition of nimotuzumab to gemcitabine (Gemzar) increases overall survival in patients with K-Ras wild-type advanced pancreatic…
ASCO 2022: Three-year follow up results from the TheraP study for metastatic prostate cancer
The Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) reports the three-year…
ASCO 2022: The updated results from the ENZAMET clinical trial
The Australian-led clinical trial ENZAMET has shown that the addition of hormone therapy with a…
ASCO 2022: Drug combination shows promise against cancer’s ‘death star’ protein
A drug combination targeting multiple mutant versions of cancer’s ‘death star’ protein has shown promise…
ASCO 2022: ctDNA may help identify the need for adjuvant therapy in stage II colon cancer
In patients with stage II colon cancer where cancer DNA was not present in the…
ASCO 2022: Lung cancer therapy could help patients live longer
Results of a Phase II clinical trial led by Cedars-Sinai Cancer investigators indicate that an immunotherapy drug…